Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06072131 · ClinicalTrials.gov registry record · Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
A Phase 3 study of Peripheral T-Cell Lymphoma, sponsored by Acrotech Biopharma.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 504
- Enrollment target
- 20
- Study locations
NCT06072131 is a Phase 3 study of Peripheral T-Cell Lymphoma that is actively recruiting participants, run by Acrotech Biopharma. The registered enrollment target is 504 participants, above the 91-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (454% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT06072131, a Phase 3 study of Peripheral T-Cell Lymphoma, is actively recruiting participants, sponsored by Acrotech Biopharma.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 504 participants
- Enrollment target
- 20
- Study locations
Study Summary
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Safety): This is a 3 Arm study. Patients with previously untreated PTCL will be randomized 1:1:1 into 1 of 3 treatment groups: 2 experimental treatment groups (Bel-CHOP or Fol-COP) or 1 active comparator treatment group (CHOP). Patients will be treated for up to 6 cycles. The primary objective is to compare the Progression Free Survival of patients with newly diagnosed PTCL treated for up to 6 cycles with Beleodaq (belinostat) in combination with CHOP (Bel-CHOP) or Folotyn (pralatrexate injection) in combination with COP (Fol-COP) to CHOP alone.
Conditions Studied
Interventions
- DRUG CHOP
- DRUG Belinostat Injection
- DRUG Pralatrexate Injection
- DRUG COP
Study Locations (20)
Other
- Universitatsmedizin Gottingen - Göttingen
- Universitaetsklinikum Halle (Saale) - Halle
- Semmelweis Egyetem - Budapest
- National Institute of Oncology - Budapest
- Markhot Ferenc Oktato Korhaz - Eger
Texas
- Valley Cancer Associates - Harlingen
- Houston Methodist Hospital - Houston
- University of Texas, MD Anderson Cancer Center - Houston
- Baylor Scott & White Medical Center - Temple - Temple
California
- University of California, San Francisco Fresno - Clovis
- University of California, Los Angeles Hem/ Onc Clinical Research Unit, Suite 600 - Santa Monica
Ontario
- The Ottawa Hospital - Ottawa
- Princess Margaret Hospital - Toronto
Colorado
- University of Colorado School of Medicine - Aurora
Florida
- Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System Memorial Cancer Institute - Pembroke Pines
Kentucky
- Norton Cancer Institute - Louisville
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 504 participants |
| Start Date | 2023-10-04 |
| Est. Completion | 2030-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06072131
The ClinicalTrials.gov registry entry for NCT06072131 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 504 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 91-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (454% higher). The listed sponsor is Acrotech Biopharma, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which CHOP is the first listed.
NCT06072131 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06072131 about?
NCT06072131 is a clinical study titled "To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL". Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Safety): This is a 3 Arm study. Patients with previously untrea...
What is the current status of trial NCT06072131?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 504 participants. The study started on 2023-10-04. Estimated completion is 2030-11.
What conditions does trial NCT06072131 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma.
What interventions are being tested in trial NCT06072131?
The interventions under investigation include: CHOP (DRUG), Belinostat Injection (DRUG), Pralatrexate Injection (DRUG), COP (DRUG).
Who is sponsoring clinical trial NCT06072131?
This trial is sponsored by Acrotech Biopharma, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06072131 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Kentucky, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
RECRUITING
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RECRUITING · Phase 1
-
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
RECRUITING · Phase 1
-
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
RECRUITING · Early Phase 1
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.